- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SMT continues earnings growth
Mobile MRI provider SMT Health Services reported its fifth straightquarter of record earnings on the strength of double-digit percentagesales growth. In its third fiscal quarter (end-September) the Pittsburgh companyearned $431,000, more than double the
Mobile MRI provider SMT Health Services reported its fifth straightquarter of record earnings on the strength of double-digit percentagesales growth.
In its third fiscal quarter (end-September) the Pittsburgh companyearned $431,000, more than double the $202,000 reported in thesame period in 1994. Third-quarter 1995 revenues were $3.9 million,compared to $3.5 million in the same period last year.
In related news, SMT has been granted approval to list its commonstock and warrants on the NASDAQ national market system underthe symbols SHED and SHEDW. The company, which operates 11 mobileMRI scanners in six states, expects its securities to begin tradingon the exchange early this month. It has been listed on the NASDAQsmall-cap index.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
